Review Article Targeting transcription factor Stat5a/b as a therapeutic strategy for prostate cancer
Zhiyong Liao, Marja T. Nevalainen
Department of Cancer Biology, Department of Medical Oncology, and Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
Received November 15, 2010; Accepted November 20, 2010; Epub November 21, 2010; Published January 1, 2011
Abstract: Signal transducer and activator of transcription 5 (Stat5) is critical for the viability and growth of human prostate cancer cells in culture and for prostate xenograft tumors in nude mice. The expression of nuclear active Stat5a/b is associated with high histological grades of clinical prostate cancers, and the presence of active Stat5a/b in prostate cancer predicts early disease recurrence. Stat5a/b and androgen receptor signaling pathways functionally synergize in prostate cancer cells, and recent work suggests that Stat5a/b may be involved in the progression of prostate cancer to metastatic disease. Here, we review the biological functions of Stat5a/b in prostate cancer and potential strategies to target the prolactin receptor (PrlR)/Jak2/Stat5 signaling pathway for therapy development for prostate cancer. (AJTR1011004).
Address all correspondence to: Marja T. Nevalainen, MD, PhD Dept. of Cancer Biology, Urology, Medical Oncology Kimmel Cancer Center, Thomas Jefferson University, 233 S. 10th Street, BLSB 309 Philadelphia, PA 19107. Email: marja.nevalainen@jefferson.edu or Marja.Nevalainen@kimmelcancercenter.org Tel: 215-503-9250 Fax: 215-503-9245